Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Farhad Aduli

Interventional Cardiology Covington, LA Medical Doctor

NPI 1023051372 CMS profile 136702

20 Starbrush Cir, Covington, LA 70433

Open in the dashboard

General payments

$6,363

383 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Farhad Aduli of Covington, LA is reported in the CMS Open Payments database as having received $6,363 across 383 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 45th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $773 31
2024 General $324 17
2023 General $821 38
2022 General $1,253 56
2021 General $1,140 76
2020 General $872 68
2019 General $1,179 97

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Farhad Aduli
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Farhad Aduli were reported at $773. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Farhad Aduli Interventional Cardiology median Middle half National median
2019 $1,179 $1,097 $329–$3,048 $163
2020 $872 $473 $161–$1,480 $114
2021 $1,140 $677 $233–$1,827 $132
2022 $1,253 $978 $333–$2,724 $149
2023 $821 $1,136 $382–$2,986 $160
2024 $324 $1,181 $395–$3,326 $164
2025 $773 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $650 24 payments
  2. Abbott Laboratories $607 33 payments
  3. Janssen Pharmaceuticals, Inc $525 41 payments
  4. AstraZeneca Pharmaceuticals LP $456 5 payments
  5. Novo Nordisk Inc $421 24 payments
  6. Sanofi-Aventis U.S. LLC $370 26 payments
  7. E.R. Squibb & Sons, L.L.C. $355 22 payments
  8. Amarin Pharma Inc. $307 19 payments
  9. Pfizer Inc. $286 16 payments
  10. Medtronic Vascular, Inc. $271 27 payments
  11. Other $2,114 146 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,948 381 payments
  2. Education $400 1 payment
  3. Travel and Lodging $15 1 payment
Products named General payments · program years 2019–2025
  1. XARELTO $525 41 payments
  2. BRILINTA $413 2 payments
  3. ELIQUIS $286 16 payments
  4. Vascepa $271 17 payments
  5. Impella $263 32 payments
  6. Ozempic $241 14 payments
  7. CAMZYOS $223 14 payments
  8. Livalo $223 15 payments
  9. SelectSecure $217 3 payments
  10. Repatha $205 16 payments
  11. Other $4,396 271 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 116 drugs

Part D claims

10,171

Median for Interventional Cardiology: 2,236

Drug cost

$1,310,858

Median for Interventional Cardiology: $380,412

Branded share of claims

30.1%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 411 $388,516
Xarelto Rivaroxaban Brand 290 $282,479
Repatha Sureclick Evolocumab Brand 281 $202,938
Entresto Sacubitril/Valsartan Brand 74 $78,964
Ozempic Semaglutide Brand 41 $60,942
Jardiance Empagliflozin Brand 48 $56,294
Mounjaro Tirzepatide Brand 37 $38,484
Multaq Dronedarone Hcl Brand 30 $31,216
Nexlizet Bempedoic Acid/Ezetimibe Brand 20 $14,751
Trulicity Dulaglutide Brand 13 $12,066

The 10 drugs with the highest cost, of 116 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 135 billing codes

Paid by Medicare

$1,782,863

Of which drugs: $6,492

Medicare patients

1,296

Average age 74

Services billed

15,056

676 women, 620 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 73%
Arthritis 50%
Diabetes 31%
Atrial fibrillation 27%
Chronic kidney disease 23%
Depression 22%
Heart failure 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 266 1,069 $6,492

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Ozempic
  • Novo Nordisk Inc $111
$111 41 —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $20
$20 — —
Wegovy
  • Novo Nordisk Inc $18
$18 — —
MULTAQ
  • SANOFI-AVENTIS U.S. LLC $16
$16 30 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $14
$14 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

383 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record